Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
Should all gun buyers receive a background check?
Should the government provide access to health care for everyone?
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for MGM Resorts International , Groupon Inc , Gilead Sciences, Inc. , Barrick Gold Corporation .
With the FDA approval of Sovaldi and Olysio , many people with hepatitis C, including those coinfected with HIV, will likely line up for long-stalled treatment.
Gilead Sciences, Inc. today announced that Health Canada has issued a Notice of Compliance for Sovaldi 400 mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitisi 1 2C infection.
A new battle is looming over access to antiviral medicines in developing countries - this time for treating hepatitis C - more than a decade after a global showdown over the price of AIDS drugs in Africa.
Gilead Sciences has announced that the FDA has approved the single tablet HIV-1 regimen Complera A for use in certain virologically-suppressed adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen.
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen CompleraA for Patients Switching from a Stable Regimen FOSTER CITY, Calif.-- --Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen CompleraA for use in certain virologically-suppressed .
Gilead Sciences today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera^A for use in certain virologically-suppressed and St. John's wort.
All day and every day, some of the stock market's best and brightest traders and money managers share their ideas, insights, and analysis in real time on Minyanville's Buzz & Banter .
" We will identify which drugs can be pitted against each other and will make some really tough formulary decisions.
A new, remarkably powerful drug that cripples the hepatitis C virus came to market last week, but it sells for $1000 per pill.
WhisperfromWallStreet issues today's Midday Healthcare Sector Most Active. Leading the most actives in this area are: - Johnson & Johnson trading at $ 91.40 down about 1.84% - Gilead Sciences, Inc. trading at $ 70.73 up about 0.17% - Pfizer Inc. trading at 30.4 down about 0.73% Johnson & Johnson has received a lot of attention today.
Nuvilex's Acquisition of Cellulose-based Live-Cell Encapsulation Technology Positions Company as a Leader in Development of Next Generation Cancer and Diabetes Treatments / Investing in the stock market takes a calibrated eye to maximize returns.
Wall Street Pennies is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout.